Anavex Life Sciences Corp (AVXL)

[seventhwave]

Why ERP/COGNISION consortium, ARIANA and practical+effective biomarker ID is an absolute must going forward

https://bit.ly/2Kn1aGh

Key quotes/info from article:

"137 Phase 2 and Phase 3 Alzheimer’s trials currently underway will require 25,000 patients per year over the next several years."

"Unfortunately, the only way to identify an accumulation of plaque in these patients is via the PET scan, which can cost between $4,000 and $6,000."

“To recruit 100 patients for a Phase 3 trial, you will test about a thousand patients, most of whom will be screened out after taking a PET scan,”

"In order to identify those 25,000 patients, between 250,000 and 500,000 individuals will need to be screened."

Observation: A blood tested biomarker ID approach that is then optionally confirmed with a PET scan will be...
1. far more economical,
2. save a great deal of time in recruitment,
3. will save potential patients the agony of being screened and rejected (9 in 10 chance) at multiple trials and
4. with the additional likelihood of a true negative diagnosis in mild cases which snowball later from a false sense of security.